Last €37.06 EUR
Change Today +0.16 / 0.43%
Volume 721.0K
As of 3:45 PM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).

fresenius se & co kgaa (FRE) Snapshot

Open
€36.98
Previous Close
€36.90
Day High
€37.20
Day Low
€36.82
52 Week High
02/17/14 - €40.20
52 Week Low
09/10/13 - €29.00
Market Cap
20.0B
Average Volume 10 Days
1.0M
EPS TTM
€2.01
Shares Outstanding
540.5M
EX-Date
05/19/14
P/E TM
18.4x
Dividend
€0.42
Dividend Yield
1.12%
Current Stock Chart for FRESENIUS SE & CO KGAA (FRE)

Related News

No related news articles were found.

fresenius se & co kgaa (FRE) Related Businessweek News

No Related Businessweek News Found

fresenius se & co kgaa (FRE) Details

Fresenius SE & Co. KGaA provides products and services for dialysis, hospital, and outpatient medical care worldwide. Its Fresenius Medical Care segment provides products for hemodialysis and peritoneal dialysis; and dialysis care services at its clinics. This segment also offers dialyzers, dialysis machines, and renal pharmaceuticals; and performs clinical laboratory tests. As of December 31, 2013, it treated patients with approximately 3,250 dialysis clinics. The company's Fresenius Kabi segment offers therapy and care products for chronically and critically ill patients. This segment provides intravenously administered generic drugs, such as anesthetics, anti-infectives, and analgesics, as well as drugs for the treatment of oncological and other critical diseases; infusion solutions and blood volume replacement products for infusion therapy; parenteral and enteral nutrition products; infusion and nutrition pumps; and transfusion technology comprising products that are used in the collection and processing whole blood and blood components, as well as in transfusion medicine. Its Fresenius Helios segment operates approximately 74 hospitals, including 51 acute care hospitals and 23 post acute care clinics; 35 outpatient facilities; and 13 nursing homes with approximately 23,000 beds. The company's Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers planning and construction services for turnkey construction projects, and medical-technical and building utilities, as well as executes projects as general contractor; and provides technical facility and operational management services, as well as replacement parts sourcing services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg, Germany.

Founded in 1912

fresenius se & co kgaa (FRE) Top Compensated Officers

Chairman of the Management Board - Fresenius ...
Total Annual Compensation: €2.4M
Chief Financial Officer of Fresenius Manageme...
Total Annual Compensation: €1.5M
Chief Executive Officer of Fresenius Kabi
Total Annual Compensation: --
Chief Legal & Compliance Officer of Fresenius...
Total Annual Compensation: €1.1M
Member of Management Board - Fresenius Manage...
Total Annual Compensation: €1.5M
Compensation as of Fiscal Year 2013.

fresenius se & co kgaa (FRE) Key Developments

Fresenius SE & Co KGaA Reports Unaudited Group Earnings Results for the Second Quarter and First Half of 2014; Provides Earnings Guidance for the Year 2014

Fresenius SE & Co KGaA reported unaudited group earnings results for the second quarter and first half of 2014. For the quarter, the group sales were to EUR 5,521 million against EUR 5,097 million a year ago. Operating income (EBIT) was EUR 785 million against EUR 732 million a year ago. Financial loss was EUR 145 million against EUR 150 million a year ago. Income before income taxes was EUR 640 million against EUR 582 million a year ago. Net income was EUR 443 million against EUR 419 million a year ago. Net income attributable to the company was EUR 259 million or EUR 1.42 per fully diluted share against EUR 258 million or EUR 1.44 per basic and fully diluted share a year ago. Net income attributable to the company was EUR 286 million or EUR 1.57 per fully diluted share against EUR 243 million or EUR 1.34 per fully diluted share a year ago. EBITDA was EUR 987 million against EUR 962 million a year ago. Operating cash flow was EUR 750 million against EUR 947 million. The decrease was mainly attributable to the payment for the W.R. Grace bankruptcy settlement of USD 115 million, increased working capital at Fresenius Medical Care and Fresenius Kabi as well as a change from annual to monthly upfront payments to Fresenius Vamed for a technical management contract all in first quarter of 2014. For the first half, the group sales were to EUR 10,733 million against EUR 9,987 million a year ago. Operating income (EBIT) was EUR 1,449 million against EUR 1,421 million a year ago. Financial loss was EUR 283 million against EUR 313 million a year ago. Income before income taxes was EUR 1,166 million against EUR 1,108 million a year ago. Net income was EUR 835 million against EUR 792 million a year ago. Net income attributable to the company was EUR 487 million or EUR 2.68 per fully diluted share against EUR 482 million or EUR 2.68 per fully diluted share a year ago. Net income attributable to the company was EUR 534 million or EUR 2.94 per fully diluted share against EUR 462 million or EUR 2.56 per fully diluted share a year ago. EBITDA was EUR 1,854 million against EUR 1,860 million a year ago. Cash flow was EUR 1,294 million against EUR 1,228 million a year ago. Operating cash flow was EUR 750 million against EUR 947 million a year ago. Capital expenditure was EUR 522 million against EUR 425 million a year ago. Net capital expenditure increased to EUR 532 million EUR 416 million a year ago. Net debt as of period end was EUR 13,457 million. For the year 2014, the company raises its sales outlook and now expects sales to increase by 14% to 16% in constant currency. Previously, the company expected sales growth of 12% to 15%. Net income guidance, and continues to expect an increase of 2% to 5% in constant currency.

Hospira Reportedly In Talks To Acquire Medical Nutrition Business

Danone (ENXTPA:BN) is in talks to sell its medical nutrition business to Hospira Inc. (NYSE:HSP). The negotiations have been going on for several weeks and, according to people familiar with the situation, both the parties are discussing the terms of a potential cash and stock deal that would value the business at close to $5 billion. The people cautioned that the talks were ongoing and no deal was certain, however. Nestlé S.A. (SWX:NESN) and Fresenius SE & Co KGaA (DB:FRE), had been interested in the medical nutrition business. However, it is not yet clear if they are still interested in the acquisition. JPMorgan has been hired by Danone to handle the sale process. Financial Times added that Danone and Hospira were not immediately available for comment.

Fresenius SE & Co. KGaA Approves Dividend

Fresenius SE & Co. KGaA announced that the Annual General Meeting of shareholders of the company was held on May 20, 2014, has approved the 21st consecutive dividend increase proposed by the general partner and the Supervisory Board. The dividend was raised by 14% to EUR 1.25 per share (2012: EUR 1.10 per share). This increase is in line with the growth in earnings per share before special items, in accordance with the new dividend policy introduced last year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FRE:GR €37.06 EUR +0.16

FRE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for FRE.
View Industry Companies
 

Industry Analysis

FRE

Industry Average

Valuation FRE Industry Range
No financial data is available for FRE.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FRESENIUS SE & CO KGAA, please visit www.fresenius.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.